Distribution and expression of mRNAs for the proto-oncogenes c-fos and c-jun in bone cells in vivo. 1998

M Oyama, and J Chiba, and Y Kato, and N Igarashi, and M Yoshida, and M Ishigami, and S Sugawara, and M Kobayashi
Department of Orthopaedic Surgery, Tokyo Women's Medical College, Daini Hospital, Japan.

In this study we assessed the expression and localization of the proto-oncogenes c-fos and c-jun in normal bone so as to gain more insight into the role of these proto-oncogenes in bone tissue. Femurs of 4-week-old rats were examined by non-radioactive in situ hybridization. cDNA probes for c-fos- and c-jun-labeled digoxygenin were produced by Polymerase Chain Reaction (PCR). C-fos and c-jun exhibited similar distribution in growth plate and bone tissue. Expression of c-fos and c-jun mRNAs in growth plate was observed in the proliferative zone and partly in the upper layer of the hypertrophic zone. In spongy bone, high expression of c-fos and c-jun mRNAs was observed in the osteoblast cytoplasm. However, there was little expression in bone lining cells. In the bony trabeculae, slight expression of c-fos and c-jun was observed in the premature osteocytes situated close to the bone surface, but no expression was detected in osteocytes that possessed relatively large lacunae in the center of the trabeculae. C-fos and c-jun were also slightly expressed in osteoclasts. These data strongly suggest that c-fos and c-jun are involved in regulating chondrocyte proliferation as immediate early genes, and may also be involved in the gene expression of bone matrix proteins as transcription factor (AP-1) in vivo. In addition, the fact that strong expression was observed in osteoblasts but hardly any expression at all in bone lining cells seems to suggest that these genes are also involved in osteoblast activation.

UI MeSH Term Description Entries
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D005269 Femur The longest and largest bone of the skeleton, it is situated between the hip and the knee. Trochanter,Greater Trochanter,Lesser Trochanter,Femurs,Greater Trochanters,Lesser Trochanters,Trochanter, Greater,Trochanter, Lesser,Trochanters,Trochanters, Greater,Trochanters, Lesser
D006132 Growth Plate The area between the EPIPHYSIS and the DIAPHYSIS within which bone growth occurs. Cartilage, Epiphyseal,Epiphyseal Cartilage,Epiphyseal Plate,Cartilages, Epiphyseal,Epiphyseal Cartilages,Epiphyseal Plates,Growth Plates,Plate, Epiphyseal,Plate, Growth,Plates, Epiphyseal,Plates, Growth
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions
D016755 Proto-Oncogene Proteins c-jun Cellular DNA-binding proteins encoded by the c-jun genes (GENES, JUN). They are involved in growth-related transcriptional control. There appear to be three distinct functions: dimerization (with c-fos), DNA-binding, and transcriptional activation. Oncogenic transformation can take place by constitutive expression of c-jun. c-fos-Associated Protein p39,c-jun Proteins,fos-Associated Protein p39,jun B Proteins,jun D Proteins,jun Proto-Oncogene Proteins,p39(c-jun),Proto-Oncogene Products c-jun,Proto-Oncogene Proteins jun,jun Proto-Oncogene Product p39,p39 c-jun,Proto Oncogene Products c jun,Proto Oncogene Proteins c jun,Proto Oncogene Proteins jun,c fos Associated Protein p39,c jun Proteins,fos Associated Protein p39,jun Proto Oncogene Product p39,jun Proto Oncogene Proteins,p39 c jun
D016760 Proto-Oncogene Proteins c-fos Cellular DNA-binding proteins encoded by the c-fos genes (GENES, FOS). They are involved in growth-related transcriptional control. c-fos combines with c-jun (PROTO-ONCOGENE PROTEINS C-JUN) to form a c-fos/c-jun heterodimer (TRANSCRIPTION FACTOR AP-1) that binds to the TRE (TPA-responsive element) in promoters of certain genes. Fos B Protein,Fos-Related Antigen,Fos-Related Antigens,c-fos Protein,c-fos Proteins,fos Proto-Oncogene Protein,fos Proto-Oncogene Proteins,p55(c-fos),Antigens, Fos-Related,FRAs,Proto-Oncogene Products c-fos,Proto-Oncogene Proteins fos,p55 c-fos,Antigen, Fos-Related,Fos Related Antigen,Fos Related Antigens,Protein, c-fos,Protein, fos Proto-Oncogene,Proto Oncogene Products c fos,Proto Oncogene Proteins c fos,Proto Oncogene Proteins fos,Proto-Oncogene Protein, fos,c fos Protein,c fos Proteins,fos Proto Oncogene Protein,fos Proto Oncogene Proteins,p55 c fos
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

M Oyama, and J Chiba, and Y Kato, and N Igarashi, and M Yoshida, and M Ishigami, and S Sugawara, and M Kobayashi
August 1996, Zygote (Cambridge, England),
M Oyama, and J Chiba, and Y Kato, and N Igarashi, and M Yoshida, and M Ishigami, and S Sugawara, and M Kobayashi
January 1990, Annual review of cell biology,
M Oyama, and J Chiba, and Y Kato, and N Igarashi, and M Yoshida, and M Ishigami, and S Sugawara, and M Kobayashi
August 1991, The Journal of investigative dermatology,
M Oyama, and J Chiba, and Y Kato, and N Igarashi, and M Yoshida, and M Ishigami, and S Sugawara, and M Kobayashi
July 2003, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine],
M Oyama, and J Chiba, and Y Kato, and N Igarashi, and M Yoshida, and M Ishigami, and S Sugawara, and M Kobayashi
August 1997, Molecular and cellular biochemistry,
M Oyama, and J Chiba, and Y Kato, and N Igarashi, and M Yoshida, and M Ishigami, and S Sugawara, and M Kobayashi
January 1990, Biomedica biochimica acta,
M Oyama, and J Chiba, and Y Kato, and N Igarashi, and M Yoshida, and M Ishigami, and S Sugawara, and M Kobayashi
May 2005, Hepatobiliary & pancreatic diseases international : HBPD INT,
M Oyama, and J Chiba, and Y Kato, and N Igarashi, and M Yoshida, and M Ishigami, and S Sugawara, and M Kobayashi
January 1993, Molecular carcinogenesis,
M Oyama, and J Chiba, and Y Kato, and N Igarashi, and M Yoshida, and M Ishigami, and S Sugawara, and M Kobayashi
January 1997, Receptors & signal transduction,
M Oyama, and J Chiba, and Y Kato, and N Igarashi, and M Yoshida, and M Ishigami, and S Sugawara, and M Kobayashi
July 1996, British journal of cancer,
Copied contents to your clipboard!